Navigation Links
Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
Date:9/4/2008

CPX-351 awarded orphan designation for the treatment of Acute Myeloid

Leukemia

PRINCETON, N.J., Sept. 4 /PRNewswire/ -- Celator Pharmaceuticals today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for the treatment of Acute Myeloid Leukemia (AML).

Celator is currently preparing to conduct two randomized Phase 2 studies with CPX-351. The first Phase 2 study, in newly diagnosed, elderly patients with AML, is expected to start enrolling patients before the end of 2008. The second study, in AML patients who have relapsed following initial treatment, is projected to start enrolling patients in the first quarter of 2009.

Interim Phase 1 data with CPX-351, where complete remissions were obtained in patients with advanced leukemia, were reported in December 2007. The company submitted additional CPX-351 preclinical and clinical data to this year's American Society of Hematology (ASH) meeting in December and will report Phase 1 results at that time.

CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown to be strongly synergistic in preclinical studies. CPX-351 was developed using Celator's proprietary CombiPlex(R) technology platform.

Orphan drug status is granted to treatments for diseases that affect fewer than 200,000 people in the United States and provides the benefits of market exclusivity for seven years, tax credits, and a waiver of FDA user fees.

"The decision by FDA to grant CPX-351 orphan drug designation reinforces the importance of developing novel products for the treatment of rare diseases and represents another milestone for the company," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "We are committed to developing products that will benefit patients and look forward to initiating enrollment in our CPX-
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
2. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
3. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
4. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
7. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
8. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
9. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
10. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
11. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) has announced ... or Foley Catheters, Intermittent Catheters and Male External or ... Trends and Forecast 2014 - 2020" report to ... global market for urinary catheters is experiencing a healthy ...
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... 9, 2011 CardioFocus, Inc., developer of the HeartLight ... Fibrillation (AF), announced its technology enables a Pulmonary Vein ... 86% of PVs remaining persistently isolated after three months. ... durable freedom from AF after a single procedure. ...
... Texas, May 9, 2011 Lexicon Pharmaceuticals, Inc. ... hold its Annual R&D Day on Thursday, May 12, 2011 ... York, New York.  Members of Lexicon,s senior management team will ... overview of several other preclinical programs in the company,s pipeline. ...
Cached Medicine Technology:New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 2New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation 3Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day 2
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... When it comes to cosmetic,injectables, the terms "investigational" ... The Physicians Coalition for,Injectable Safety offers consumers these ... consumer safety information is required by,the Food and ... has been,approved," explained Coalition leader Roger Dailey, MD ...
... of the most exciting scientific and clinical areas. Every ... rulings by regulatory bodies, or ethical controversies often ... as well as ethicists, legislators, the media and the ... more than 5,000 of the worlds leading experts in ...
... ... WHO: Antonio Garcia from Frost & Sullivan,s Healthcare Consulting ... Image Management Consultants, will share industry ... volumes of medical images and protecting ...
... CEO, and Chairman Issues Shareholder Letter, ... CEO and Chairman of BioElectronics, Corp. (Pink ... anti-inflammatory patch,with an embedded battery operated microchip ... and speed healing, today issued the,following letter ...
... Teleconference to be Held at 8:30 a.m. EDT, ... (Nasdaq: FFHL ) (,Fuwei, or ,the Company,), a,manufacturer ... announced the financial results for the fourth quarter and ... Highlights, -- Revenues for 2007 rose 2.9% to ...
... A new member-based,organization, Practice Greenhealth, has ... Practice Greenhealth reflects the combined experience,of three ... of,the healthcare sector: Hospitals for a Healthy ... and the Healthcare Clean Energy Exchange., ...
Cached Medicine News:Health News:Clarity on Cosmetic Injectable Labeling and Use 2Health News:Clarity on Cosmetic Injectable Labeling and Use 3Health News:European Society of Human Reproduction & Embryology 24th annual meeting 2Health News:Protecting Patient Images From Damage and Disaster 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 3Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 2Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 3Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 4Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 5Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 6Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 7Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 8Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 9Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 10Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 11Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 12Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 13Health News:Fuwei Films Announces Fourth Quarter and Full Year 2007 Financial Results 14Health News:Practice Greenhealth Hires First Exec 2
McIntyre-Binkhorst, length 18 mm....
Binkhorst, length 35 mm....
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening....
Army/Navy retractor (set of 2)....
Medicine Products: